[go: up one dir, main page]

MX2018006800A - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX2018006800A
MX2018006800A MX2018006800A MX2018006800A MX2018006800A MX 2018006800 A MX2018006800 A MX 2018006800A MX 2018006800 A MX2018006800 A MX 2018006800A MX 2018006800 A MX2018006800 A MX 2018006800A MX 2018006800 A MX2018006800 A MX 2018006800A
Authority
MX
Mexico
Prior art keywords
formoterol
solvates
pharmaceutical composition
pharmaceutically acceptable
salts
Prior art date
Application number
MX2018006800A
Other languages
English (en)
Other versions
MX375783B (es
Inventor
Corr Stuart
James Noakes Timothy
Original Assignee
Mexichem Fluor Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57750288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018006800(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1521456.2A external-priority patent/GB201521456D0/en
Priority claimed from GB1615916.2A external-priority patent/GB2554092A/en
Application filed by Mexichem Fluor Sa De Cv filed Critical Mexichem Fluor Sa De Cv
Publication of MX2018006800A publication Critical patent/MX2018006800A/es
Publication of MX375783B publication Critical patent/MX375783B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe una composición farmacéutica. La composición comprende: (i) al menos un compuesto de formoterol seleccionado de formoterol, sales de formoterol farmacéuticamente aceptables, profármacos de formoterol, solvatos de formoterol, solvatos de sales de formoterol farmacéuticamente aceptables y solvatos de profármacos de formoterol; (ii) al menos un corticosteroide; (iii) un componente tensioactivo que comprende al menos un compuesto tensioactivo; y (iv) un componente propelente que comprende 1,1-difluoroetano (R-152a).
MX2018006800A 2015-12-04 2016-12-02 Composiciones farmacéuticas que comprenden un compuesto de formoterol, un corticosteroide y un componente propelente. MX375783B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1521456.2A GB201521456D0 (en) 2015-12-04 2015-12-04 Pharmaceutical composition
GB1615916.2A GB2554092A (en) 2016-09-19 2016-09-19 Pharmaceutical composition
PCT/GB2016/053812 WO2017093758A1 (en) 2015-12-04 2016-12-02 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
MX2018006800A true MX2018006800A (es) 2018-11-09
MX375783B MX375783B (es) 2025-03-07

Family

ID=57750288

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006800A MX375783B (es) 2015-12-04 2016-12-02 Composiciones farmacéuticas que comprenden un compuesto de formoterol, un corticosteroide y un componente propelente.

Country Status (10)

Country Link
US (3) US11559505B2 (es)
EP (4) EP3383366B2 (es)
JP (3) JP6899824B2 (es)
CN (2) CN108289843B (es)
AU (3) AU2016364650B2 (es)
BR (2) BR112018011266B1 (es)
CA (1) CA3007050C (es)
ES (3) ES2866175T3 (es)
MX (1) MX375783B (es)
WO (1) WO2017093758A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3383366B2 (en) 2015-12-04 2024-06-05 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
PE20191043A1 (es) 2016-09-19 2019-08-06 Mexichem Fluor Sa De Cv Composicion farmaceutica
US20190374519A1 (en) * 2016-09-19 2019-12-12 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
US11260052B2 (en) 2016-09-19 2022-03-01 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
JP6781828B2 (ja) 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
CN113069417A (zh) * 2016-09-19 2021-07-06 墨西哥氟石股份公司 药物组合物
CN109771398B (zh) * 2019-02-25 2019-09-20 广州南鑫药业有限公司 一种帕拉米韦溶液型吸入剂及其制备方法
GB2584686A (en) * 2019-06-11 2020-12-16 Mexichem Fluor Sa De Cv Methods
CN110840864B (zh) * 2019-12-20 2022-02-22 广州健康元呼吸药物工程技术有限公司 一种β2受体激动剂吸入气雾剂及包含该吸入气雾剂的产品
PE20221867A1 (es) * 2020-01-28 2022-12-02 Chiesi Farm Spa Inhaladores de dosis medida presurizada que comprenden una formulacion farmaceutica amortiguada
GB202001537D0 (en) 2020-02-05 2020-03-18 Consort Medical Plc Pressurised dispensing container
AU2021223587A1 (en) * 2020-02-20 2022-09-29 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
CN116338014A (zh) * 2021-12-23 2023-06-27 上海医药工业研究院有限公司 一种吸入用药物组合物的组分分离检测方法
FR3137830A1 (fr) * 2022-07-13 2024-01-19 Aptar France Sas Composition pharmaceutique comprenant du salbutamol

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
MX9203481A (es) 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US6123924A (en) 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
DK0613371T3 (da) * 1991-12-18 2002-05-13 Astrazeneca Ab Ny kombination af formoterol og budesonid
CN1088580C (zh) 1994-12-22 2002-08-07 阿斯特拉公司 气溶胶药物制剂
ES2276736T3 (es) 1995-04-14 2007-07-01 Smithkline Beecham Corporation Inhalador medidor de dosis para propionato de flucticasona.
JP2001511160A (ja) 1997-02-05 2001-08-07 ヤゴ リサーチ アクチェンゲゼルシャフト 医学用エアゾール配合物
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
KR100589926B1 (ko) 1997-09-29 2006-06-15 넥타르 테라퓨틱스 천공된 미립자 및 사용 방법
US6103266A (en) 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DK1102579T3 (da) 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
GB2392164B (en) 1999-09-11 2004-04-07 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
UA73986C2 (uk) 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
CN1144582C (zh) 2000-11-28 2004-04-07 中国药科大学 治疗呼吸系统疾病的无氟里昂药用气雾剂
AR036358A1 (es) 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US8039746B2 (en) 2002-08-08 2011-10-18 Fujikura Ltd. Electric connector and cable
GB0323685D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
US20060018840A1 (en) 2004-06-28 2006-01-26 Nektar Therapeutics Aerosolizable formulation comprising nicotine
ES2259915B1 (es) * 2005-03-15 2007-12-16 Laboratorio Aldo-Union, S.A. Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion.
WO2007020204A2 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
DE102006017320A1 (de) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
WO2008097233A1 (en) 2007-02-09 2008-08-14 Schering Corporation Stable pharmaceutical drug aerosols
US8597616B2 (en) * 2007-10-22 2013-12-03 Board Of Regents Of The University Of Texas System Dry powder drug delivery formulations, methods of use, and devices therefore
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
GB0915106D0 (en) 2009-08-28 2009-10-07 Glaxo Group Ltd Process
DK2727582T3 (en) * 2009-10-02 2016-05-17 Chiesi Farma Spa Pharmaceutical aerosol formulations of formoterol and beclomethasone dipropionate
PT2515854E (pt) 2009-12-23 2014-05-27 Chiesi Farma Spa Formulação de aerossol para dpoc
RU2568882C2 (ru) * 2010-07-16 2015-11-20 Сипла Лимитед Фармацевтические композиции
EP2749280A3 (en) * 2011-02-17 2014-08-20 Cipla Limited Combination of glycopyrronium and formoterol
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
WO2014016548A2 (en) 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
JP2016503390A (ja) 2012-10-23 2016-02-04 シプラ・リミテッド 医薬組成物
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
CA2935305C (en) 2013-12-30 2022-07-12 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
EP3383366B2 (en) 2015-12-04 2024-06-05 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
JP6781828B2 (ja) 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物

Also Published As

Publication number Publication date
AU2019202874C1 (en) 2020-08-06
BR122020022602B1 (pt) 2024-03-05
CN108289843B (zh) 2021-08-17
EP3556347B1 (en) 2021-03-24
JP2020073515A (ja) 2020-05-14
BR112018011266A2 (pt) 2018-11-21
EP3383366A1 (en) 2018-10-10
US20200009089A1 (en) 2020-01-09
AU2016364650A1 (en) 2018-06-21
EP3556348B1 (en) 2021-02-03
MX375783B (es) 2025-03-07
AU2019202874A1 (en) 2019-05-16
EP3383366B1 (en) 2020-03-25
JP6899824B2 (ja) 2021-07-07
US11559507B2 (en) 2023-01-24
US20200069619A1 (en) 2020-03-05
JP6899889B2 (ja) 2021-07-07
JP2020073516A (ja) 2020-05-14
EP3701940B1 (en) 2025-11-12
EP3556347A1 (en) 2019-10-23
AU2019202874B2 (en) 2020-03-12
EP3383366B2 (en) 2024-06-05
AU2016364650B2 (en) 2019-04-04
US11559505B2 (en) 2023-01-24
CA3007050C (en) 2020-12-08
ES2869176T3 (es) 2021-10-25
EP3556348A1 (en) 2019-10-23
ES2796177T3 (es) 2020-11-26
CA3007050A1 (en) 2017-06-08
AU2019202875B2 (en) 2020-03-12
EP3701940A1 (en) 2020-09-02
BR112018011266B1 (pt) 2023-11-21
US11559506B2 (en) 2023-01-24
ES2796177T5 (es) 2024-10-29
ES2866175T3 (es) 2021-10-19
JP2019500340A (ja) 2019-01-10
CN112472689A (zh) 2021-03-12
US20190247339A1 (en) 2019-08-15
AU2019202875A1 (en) 2019-05-16
WO2017093758A1 (en) 2017-06-08
CN108289843A (zh) 2018-07-17
JP6931383B2 (ja) 2021-09-01
CN112472689B (zh) 2023-01-17

Similar Documents

Publication Publication Date Title
MX2018006800A (es) Composicion farmaceutica.
MX2018006799A (es) Composicion farmaceutica.
UY36151A (es) ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?.
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
CL2019003610A1 (es) Un esteroide 19 nor-c21-n-pirazolilo c3,3-disustituido cristalino. (divisional solicitud 201900477).
MX392213B (es) Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
CL2018002410A1 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
ZA201902051B (en) Pharmaceutical composition
MX2017014645A (es) Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
MX376028B (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
MX387725B (es) Composición farmacéutica.
MX418110B (es) Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas
ZA201902052B (en) Pharmaceutical composition
MX386732B (es) Composición farmacéutica de corticosteroide soluble.
ZA201902049B (en) Pharmaceutical composition
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
MX2022007623A (es) Combinaciones.
PH12017502426A1 (en) Solid pharmaceutical compositions for treating hcv
CL2019001859A1 (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta.
PE20200749A1 (es) Moduladores de la expresion de enac
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
PH12018500132A1 (en) Solid pharmaceutical compositions for treating hcv
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
MX2019001425A (es) Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea.
MX2019000977A (es) Composiciones farmacéuticas a base de curcumina y procedimientos para su fabricación.

Legal Events

Date Code Title Description
FG Grant or registration